Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

NCT04610671 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Muscle-Invasive Bladder Carcinoma
Bladder Cancer

Interventions

DRUG: CG0070
DRUG: Nivolumab

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]